ABO血型系统
医学
四分位间距
内科学
观察研究
血小板
单变量分析
血小板输注
多元分析
胃肠病学
作者
Katerina Pavenski,Theodore E. Warkentin,Hua Shen,Yang Liu,Nancy M. Heddle
出处
期刊:Transfusion
[Wiley]
日期:2010-02-26
卷期号:50 (7): 1552-1560
被引量:48
标识
DOI:10.1111/j.1537-2995.2010.02602.x
摘要
BACKGROUND: Major incompatible platelet (PLT) transfusions have been associated with inferior posttransfusion PLT count increments compared with ABO‐compatible transfusions. However, most studies to date have been small and involved hematology/oncology patients. STUDY DESIGN AND METHODS: We conducted a prospective observational study in predominantly nononcologic patients to determine whether ABO‐compatible (defined as ABO identical and minor incompatible) PLT transfusions resulted in superior posttransfusion PLT count increments. We collected data on consecutive inpatients at Hamilton General Hospital receiving a PLT transfusion during a 50‐month period. We compared the absolute count increment (ACI) and corrected count increment (CCI) values in ABO‐compatible versus incompatible PLT transfusions. Linear regression was performed to adjust for factors potentially affecting the posttransfusion PLT count response. Univariate models were applied to each explanatory variable with p values of less than 0.10 considered potentially significant. Multivariate models were applied to all potential explanatory variables of interest. p values of less than 0.05 were considered significant. RESULTS: A total of 1030 transfusions were included in the primary analysis, 73.7% of which were ABO compatible. The median ACI was 35 (interquartile range [IQR], 18‐55) for compatible transfusions versus 31 (IQR, 13‐51) for incompatible transfusions (p = 0.1480). The median posttransfusion CCI (n = 686) was 18.6 (IQR, 10.2‐28.4) for compatible transfusions versus 15.2 (IQR, 4.7‐25.7) for incompatible transfusions (p = 0.0499). CONCLUSIONS: ABO‐compatible transfusions in nononcologic patients are associated with a significantly better CCI although the observed difference is small (approx. 20%) and may not be clinically significant.
科研通智能强力驱动
Strongly Powered by AbleSci AI